ATE498402T1 - Clc-2-kanalöffner zur behandlung von magen- oder darm-ulcus - Google Patents
Clc-2-kanalöffner zur behandlung von magen- oder darm-ulcusInfo
- Publication number
- ATE498402T1 ATE498402T1 AT02781814T AT02781814T ATE498402T1 AT E498402 T1 ATE498402 T1 AT E498402T1 AT 02781814 T AT02781814 T AT 02781814T AT 02781814 T AT02781814 T AT 02781814T AT E498402 T1 ATE498402 T1 AT E498402T1
- Authority
- AT
- Austria
- Prior art keywords
- ulcus
- clc
- intestinal
- stomach
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33154201P | 2001-11-19 | 2001-11-19 | |
PCT/JP2002/012037 WO2003043639A2 (en) | 2001-11-19 | 2002-11-19 | PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE498402T1 true ATE498402T1 (de) | 2011-03-15 |
Family
ID=23294388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02781814T ATE498402T1 (de) | 2001-11-19 | 2002-11-19 | Clc-2-kanalöffner zur behandlung von magen- oder darm-ulcus |
Country Status (12)
Country | Link |
---|---|
US (2) | US7732487B2 (de) |
EP (2) | EP1455794B1 (de) |
JP (1) | JP4377692B2 (de) |
AR (1) | AR037556A1 (de) |
AT (1) | ATE498402T1 (de) |
AU (1) | AU2002348670A1 (de) |
CA (1) | CA2466906C (de) |
DE (1) | DE60239220D1 (de) |
DK (1) | DK1455794T3 (de) |
ES (1) | ES2359804T3 (de) |
TW (1) | TWI263505B (de) |
WO (1) | WO2003043639A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR037524A1 (es) | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
US8114911B2 (en) * | 2002-10-23 | 2012-02-14 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
MXPA05006981A (es) * | 2002-12-27 | 2005-12-14 | Sucampo Ag | Derivados de prostaglandinas para el tratamiento de la molestia abdominal. |
DE602004030245D1 (de) | 2003-07-03 | 2011-01-05 | Sucampo Ag | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
TWI387454B (zh) | 2004-09-02 | 2013-03-01 | Sucampo Ag | 治療胃腸道疾病之方法及組成物 |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
RU2468800C2 (ru) * | 2005-04-12 | 2012-12-10 | Сукампо Аг | Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний |
CA2608457C (en) * | 2005-05-17 | 2013-09-10 | Santen Pharmaceutical Co., Ltd. | Ebselen as a prophylactic or therapeutic agent for corneal or conjunctival disorders |
US20080207759A1 (en) * | 2007-02-27 | 2008-08-28 | Sucampo Ag | Method for protecting mitochondria |
JP5314931B2 (ja) * | 2007-05-25 | 2013-10-16 | 参天製薬株式会社 | 加齢黄斑変性の予防又は治療剤 |
US20090030072A1 (en) | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
JP2017052723A (ja) * | 2015-09-10 | 2017-03-16 | 株式会社Lttバイオファーマ | ドライアイ改善剤 |
JP6710040B2 (ja) * | 2015-11-06 | 2020-06-17 | 江崎グリコ株式会社 | 唾液分泌促進剤及び口腔用組成物 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225439A (en) | 1987-01-28 | 1993-07-06 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
CA1323364C (en) | 1987-01-28 | 1993-10-19 | Ryuzo Ueno | Prostaglandins e and anti ulcer agents containing same |
US5380709A (en) | 1987-01-28 | 1995-01-10 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
DE3873007T2 (de) | 1987-10-02 | 1992-12-03 | Ueno Seiyaku Oyo Kenkyujo Kk | Kathartica. |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体 |
CA2027814C (en) | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
US5256696A (en) | 1989-11-22 | 1993-10-26 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds |
CA2030346C (en) | 1989-11-22 | 2000-04-11 | Ryuji Ueno | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds |
US5254588A (en) | 1989-11-22 | 1993-10-19 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds |
CA2030344C (en) | 1989-11-22 | 2000-04-18 | Ryuji Ueno | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds |
DE69130586T2 (de) | 1990-05-01 | 1999-06-17 | R Tech Ueno Ltd | Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten |
US5100647A (en) | 1990-10-02 | 1992-03-31 | The Trustees Of The University Of Pennsylvania | Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment |
CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
US6015828A (en) | 1996-05-31 | 2000-01-18 | Cuppoletti; John | Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases |
ATE401894T1 (de) | 1997-11-28 | 2008-08-15 | Sucampo Ag | Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten |
TWI225398B (en) | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
BR0016021A (pt) * | 1999-12-22 | 2003-07-15 | Inspire Pharmaceuticals Inc | Processo de tratamento de doenças do trato gastrointestinal com agonistas do receptor purinérgico |
EP1267883B1 (de) | 2000-04-06 | 2009-06-17 | Sucampo AG | Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält |
US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
TWI302100B (en) | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
CA2458471C (en) | 2001-08-31 | 2012-07-31 | Sucampo Ag | Prostaglandin analogs as chloride channel opener |
-
2002
- 2002-11-18 US US10/298,062 patent/US7732487B2/en not_active Expired - Fee Related
- 2002-11-18 TW TW91133604A patent/TWI263505B/zh not_active IP Right Cessation
- 2002-11-19 DK DK02781814T patent/DK1455794T3/da active
- 2002-11-19 AU AU2002348670A patent/AU2002348670A1/en not_active Abandoned
- 2002-11-19 JP JP2003545320A patent/JP4377692B2/ja not_active Expired - Fee Related
- 2002-11-19 EP EP20020781814 patent/EP1455794B1/de not_active Expired - Lifetime
- 2002-11-19 EP EP10010108A patent/EP2364708A3/de not_active Withdrawn
- 2002-11-19 AT AT02781814T patent/ATE498402T1/de active
- 2002-11-19 AR ARP020104435 patent/AR037556A1/es not_active Application Discontinuation
- 2002-11-19 CA CA 2466906 patent/CA2466906C/en not_active Expired - Fee Related
- 2002-11-19 ES ES02781814T patent/ES2359804T3/es not_active Expired - Lifetime
- 2002-11-19 DE DE60239220T patent/DE60239220D1/de not_active Expired - Lifetime
- 2002-11-19 WO PCT/JP2002/012037 patent/WO2003043639A2/en active Application Filing
-
2010
- 2010-04-16 US US12/761,979 patent/US20100204332A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003043639A3 (en) | 2004-02-19 |
EP1455794A2 (de) | 2004-09-15 |
JP2005515186A (ja) | 2005-05-26 |
DK1455794T3 (da) | 2011-03-14 |
US7732487B2 (en) | 2010-06-08 |
TWI263505B (en) | 2006-10-11 |
US20100204332A1 (en) | 2010-08-12 |
US20030166632A1 (en) | 2003-09-04 |
AU2002348670A1 (en) | 2003-06-10 |
EP2364708A3 (de) | 2011-12-28 |
AR037556A1 (es) | 2004-11-17 |
DE60239220D1 (de) | 2011-03-31 |
EP1455794B1 (de) | 2011-02-16 |
ES2359804T3 (es) | 2011-05-27 |
JP4377692B2 (ja) | 2009-12-02 |
TW200304829A (en) | 2003-10-16 |
CA2466906C (en) | 2011-10-18 |
CA2466906A1 (en) | 2003-05-30 |
WO2003043639A2 (en) | 2003-05-30 |
EP2364708A2 (de) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE498402T1 (de) | Clc-2-kanalöffner zur behandlung von magen- oder darm-ulcus | |
NO20035610L (no) | Fremgangsmate for behandling av vaeskeformig hydrokarbon | |
ATE293610T1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60218451D1 (de) | 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation | |
ATE384522T1 (de) | Medikamente zur chemotherapeutischen behandlung von erkrankungen | |
DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
DE60211740D1 (de) | Zusammensetzung zur saatgutbehandlung | |
ATE414512T1 (de) | Kombinationstherapie zur behandlung von krebs | |
DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
ATE413375T1 (de) | Retinoide zur behandlung von emphysem | |
ATE313540T1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
DE60233186D1 (de) | Verbessertes System zur Behandlung von Elementarschwefel-Rückständen | |
DE60030554T8 (de) | Verwendungen von et743 zur behandlung von krebs | |
ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE60236743D1 (de) | Zur behandlung androgenabhängiger krankheiten | |
ATE522218T1 (de) | Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung | |
DE60211913D1 (de) | Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz | |
DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
DE60214355D1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
DE60203207D1 (de) | Zange zur orthodontischen Behandlung | |
FI20012170A (fi) | Menetelmä lauhteiden käsittelemiseksi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1455794 Country of ref document: EP |